Venclexta Approved for Specific Genetic Blood Cancer

MONDAY, April 11, 2016 — Venclexta (venetoclax) has been approved by the U.S. Food and Drug Administration to treat chronic lymphocytic leukemia (CLL) characterized by a specific chromosomal abnormality called the 17p deletion.
People with this…
Source: Topamax